Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.

Suzhou Fushilai Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and raw materials for health care products. The Company's main products include three series of lipoic acid series, phosphatidylcholine series and carnosine series. The Company mainly conducts its business in domestic and overseas markets such as Europe, America, Japan and South Korea, India and South America.